Form 4/A for BMEA Biomea Fusion, Inc.
Accepted 2023-04-06 00:00:00 ET · period of report 2023-03-31 · accession 0001859061-23-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2023-04-06 | 2023-03-31 | BMEA | A2A Pharmaceuticals, Inc. | 10% | S - Sale | $31.25 | -200.0K | 4.10M | -5% | -$6.25M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-31 | S | D | 200,000 | $31.25 | 4,100,000 | D | — | — | (F1) A total of 200,000 shares were sold at an average price of 31.25 in multiple transactions ranging in price from 30.87 to 31.64. Additional details of the individual transactions are available upon request. |